/
Navigation
Chronicles
Browse all articles
Explore
Semantic exploration
Research
Entity momentum
Nexus
Correlations & relationships
Story Arc
Topic evolution
Drift Map
Semantic trajectory animation
Posts
Analysis & commentary
Pulse API
Tech news intelligence API
Browse
Entities
Companies, people, products, technologies
Domains
Browse by publication source
Handles
Browse by social media handle
Detection
Concept Search
Semantic similarity search
High Impact Stories
Top coverage by position
Sentiment Analysis
Positive/negative coverage
Anomaly Detection
Unusual coverage patterns
Analysis
Rivalry Report
Compare two entities head-to-head
Semantic Pivots
Narrative discontinuities
Crisis Response
Event recovery patterns
Connected
Search: /
Command: ⌘K
Embeddings: large
TEXXR

Chronicles

The story behind the story

days · browse · Enter similar · o open

Experts say the Apple Watch has yet to change patient management and treatment as Apple has failed to make inroads with most doctors

Device touted as ‘future of health’ has yet to change the way patients are treated, say experts  —  As a researcher at Harvard, Shruthi Mahalingaiah

Financial Times Patrick McGee

Context & Ripple Effects

The arc here runs from promise to stall: back in 2015 the FDA signaled a 'very light touch' regulatory approach to the Apple Watch, and by 2018 analysts were framing the device as poised to disrupt healthcare diagnostics entirely. Seven years on, experts including Harvard researcher Shruthi Mahalingaiah say that disruption hasn't materialized — patient management and treatment look largely unchanged.

First-order effects

  • Most doctors have not adopted the Apple Watch into clinical practice, leaving its 'future of health' positioning unfulfilled for the patients and clinicians Apple targeted.
  • Apple's push for FDA approvals has fallen short of what broader physician acceptance requires, keeping the device on the consumer side of the line.

Second-order effects

  • Hardware ambitions are slipping under accuracy pressure: Apple delayed adding a blood pressure monitor to the Watch until 2024, possibly 2025, after difficulties during testing (the blood pressure monitor delay) — narrowing the feature set that could win over skeptical clinicians.
  • The 2024 follow-up coverage shows some individual doctors using the Watch to diagnose and help manage conditions despite limited institutional uptake, pointing to bottom-up experimentation rather than systematic integration.

Third-order effects

  • If the pattern holds, consumer wearables stay adjunct tools rather than clinical infrastructure, with device makers needing both sensor accuracy and regulatory clearance before physicians treat wrist data as actionable — a bar the 2018 disruption thesis underestimated.

The trend: Consumer health wearables are stalling at the clinic door: sensor accuracy and FDA clearance, not feature marketing, now gate whether devices like the Apple Watch change how patients are actually treated.